Litcius/Paper detail

Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor

Yu Cai, Jianlin He, Zhipeng Wu, Weigang He, Xiaoming Dai, Yan Xu, Min Cheng, Na Yang, Yongxin Ren, Guanglin Wang, Jian Wang, Yang Sai, Hong Jia, Guangxiu Dai, Xiong Li, Weiguo Su

2023Journal of Pharmacology and Experimental Therapeutics10 citationsDOIOpen Access PDF

Topics & Concepts

SykMedicineImmune systemImmunologyCancer researchPharmacologyB cellAutoimmune diseaseReceptorTyrosine kinaseAntibodyInternal medicineMast cells and histamineMonoclonal and Polyclonal Antibodies ResearchPlatelet Disorders and Treatments
Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor | Litcius